Tag: Aesthetics

Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

Oral presentations include:

  • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
  • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
  • Presenter: Joely Kaufman, MD
  • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11th, 10:27 a.m.

    The following posters will be on display and available for the entire length of the ASDS Virtual Annual Meeting.

    • Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
    • Authors: Sue Ellen Cox, John H. Joseph, Steven Fagien, Dee Anna Glaser, Suzanne Bruce, Edward Lain, Steven Yoelin, Melanie Palm, Corey S. Maas, Xiaofang Lei, John Maltman, Sara Sangha, Mitchell Brin
  • Global Patient Perspectives on Skin Quality in Facial Aesthetics
    • Authors: Noëlle Sherber, Annie Chiu, Arisa Ortiz, Shannon Humphrey, Jeanine Downie, Sabrina Fabi

    Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.

    IMPORTANT SAFETY INFORMATION & APPROVED USES
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general

    Continue reading

    Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting | Nachricht

    IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ –Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

    The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

    Oral presentations include:

    • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
    • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
    • Presenter: Joely Kaufman, MD
    • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11th, 10:27 a.m.

    The following posters will be on display and available for the entire length of the ASDS Virtual Annual Meeting.

    • Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
    • Authors: Sue Ellen Cox, John H. Joseph, Steven Fagien, Dee Anna Glaser, Suzanne Bruce, Edward Lain, Steven Yoelin, Melanie Palm, Corey S. Maas, Xiaofang Lei, John Maltman, Sara Sangha, Mitchell Brin
  • Global Patient Perspectives on Skin Quality in Facial Aesthetics
    • Authors: Noëlle Sherber, Annie Chiu, Arisa Ortiz, Shannon Humphrey, Jeanine Downie, Sabrina Fabi

    Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.

    IMPORTANT SAFETY INFORMATION & APPROVED USES
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general muscle weakness,

    Continue reading

    Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery’s Annual Meeting (ASDS)

    DUBLIN, Oct. 9, 2020 /PRNewswire/ — Endo International plc (NASDAQ:ENDP) today announced that data relevant to the use of Endo Aesthetics’ Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women will be featured during the American Society for Dermatologic Surgery’s Annual Meeting (ASDS). These data will be highlighted in three posters and two oral presentations during the virtual meeting taking place October 9 – 11, 2020.

    Oral Presentations

    On Friday, October 9th a presentation titled “Results From a 1000+ Subject Survey Assessing Satisfaction With a Hypothetical 1-Point Improvement on the Validated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) Analysis,” will be given by Sabrina Fabi, M.D., a board-certified dermatologist in California. Dr. Fabi will share results from a study designed to determine if a 1-point improvement in PR-PCSS score is a clinically meaningful outcome and will highlight the importance of patient education during consultations.

    On Sunday, October 11th, Melanie Palm, M.D., will present “Real-World Effectiveness and Safety of Collagenase Clostridium Histolyticum-aaes Injections for the Treatment of Thigh Cellulite in Women: An Interim Analysis”. During this presentation, Dr. Palm, a board-certified dermatologist and cosmetic surgeon in California, will outline the 90-day findings from ongoing phase 3b REAL™ and PIXELS™ studies assessing not only investigator-perceived and patient-reported results at 90-days, but also the quantitative corroboration of these findings, with 3D-image scans.

    Poster Presentations

    All poster presentations will be available for ASDS attendees throughout the Congress.

    • Title: Long-Term Durability of Collagenase Clostridium Histolyticum-aaes Treatment Effectiveness for Cellulite in Women
    • Authors: Joely Janette Kaufman, M.D., Vernon Leroy Young, M.D., Matthew Zook, M.D., Saji Vijayan, MBBS, D.Diab., Michael McLane PhD., Xiang Q Ph.D., Chajko KA, Lawrence Bass, M.D.
       
  • Title: Patient Retention Strategies for Long-Term Extension Aesthetic Studies: Collagenase Clostridium Histolyticum-aaes (QWO™) Phase 3 Clinical Study Experience
    • Authors: Joely Janette Kaufman, M.D., James Clark M.D., Kappa Peddy, M.D., Alex Cazzaniga Ph.D., Davina Cupo, Robert Yon, Rosalie Filling
       
  • Title: A Survey of Dermatology Healthcare Professional Knowledge, Perception, and Experience Regarding Cellulite and Its Treatment
    • Authors: Jill Edgecombe, Daniel Connolly, Sherry Chen, Stephanie Wenstrup

    “We are pleased with the breadth and depth of the data that will be presented at the ASDS meeting,” said Matthew Davis, M.D., R.Ph., Senior Vice President and Chief Medical Officer of Endo. “Endo Aesthetics is committed to offering aesthetic healthcare providers data not only on the safety and efficacy of QWO, but also on the real world implications of this treatment, including patient retention and perceptions, as we prepare for the product’s launch in spring 2021.”

    INDICATION
    QWO is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

    IMPORTANT SAFETY INFORMATION FOR QWO CONTRAINDICATIONS
    QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

    WARNINGS AND PRECAUTIONS
    Hypersensitivity Reactions
    Serious hypersensitivity

    Continue reading